Brought to you by 
Series B brings in $18mm for Stentys;later adds to round
29 Jun 2009
Executive Summary
Scottish Equity Partners has led Stentys's $18mm Series B venture round. Returning backer Sofinnova Partners also participated. A representative from SEP will take a seat on the company's board. Stentys will use the funds to finish clinical trials and gain the CE Mark for its drug-eluting bifurcated stent.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B brings in $18mm for Stentys;later adds to round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice